Table 1.
Study Characteristics and Basic Cohort Demographics
| Study | Primary Location | Designa | Study Period | Cohort Size, No. | Female, No., % | Median Age at First Treatment, y | LGG Included | NF1, No., % | Mean Follow-Up After Bevacizumab, mo |
|---|---|---|---|---|---|---|---|---|---|
| Zhukova et al, 201923 | Melbourne, Australia | R OCS (2) | 2014-2017 | 15 | 6, 40% | 7 | 9 PA, 1 PXA, 1 GG, 4 RC | 2, 13% | 11 |
| Gorsi et al, 201819 | San Diego, CA, US | R OCS (1) | 2012-2017 | 15 | 10, 67% | 7 | 10 PA (2 OPG), 4 LGG, 1 RC | 1, 7% | 5 |
| Kalra et al, 201522 | Sydney, Australia | R OCS (1) | 2009-2013 | 16 | 7, 44% | 8.6 | 10 PA (6 OPG), 1 PXA, 1 LGG, 4 RC | 5, 31% | 9.2 |
| Hsu et al, 201521 | Stanford University, Palo Alto, CA, US | R OCS (1) | 2009-2013 | 8 | 2, 25% | 4.8 | 4 OPG (1 RC), 3 PA, 1 GG | 2, 25% | 49 |
| Gururangan et al, 201420 | Duke University, Durham, NC, US | P OCS (multiple) | 2008-2010 | 35 | NR | 8.4 | 16 PA, 12 OPG (12 RC), 1 GG, 1 LGG | 5, 15% | 5.1 |
| Hwang et al, 201213 | Washington, DC, US | R OCS (4) | 2006-2009 | 14 | NR | 5.3 | 4 PA, 4 LGG, 6 RC (4 OPG) | 3, 21% | >12 |
| Couec et al, 201218 | Nantes, France | R OCS (7) | 2007-2010 | 7 | NR | 10 | 7 PA (2 OPG) | NR | 12 |
Abbreviations: GG, ganglioglioma; LGG, low-grade glioma; NF1, neurofibromatosis 1; NR, not reported; OCS, observational cohort study; OPG, optic pathway glioma; P, prospective; PA, pilocytic astrocytoma; PXA, pleomorphic xanthroastrocytoma; R, retrospective; RC, radio-clinical; US, United States of America.
aNumber of institutions involved in parentheses.